Cargando…

The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure

OBJECTIVES: To find the imaging mortality predictors in patients with previous myocardial infarction (MI), symptomatic heart failure (HF), and reduced left ventricle (LV) ejection fraction (EF). METHODS: for the study 39 patients were selected prospectively with prior MI, symptomatic HF, and LVEF ≤4...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazakauskaite, Egle, Vajauskas, Donatas, Bardauskiene, Lina, Ordiene, Rasa, Zabiela, Vytautas, Zaliaduonyte, Diana, Gustiene, Olivija, Lapinskas, Tomas, Jurkevicius, Renaldas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466976/
https://www.ncbi.nlm.nih.gov/pubmed/35503304
http://dx.doi.org/10.1177/02676591221100739
_version_ 1785099011558998016
author Kazakauskaite, Egle
Vajauskas, Donatas
Bardauskiene, Lina
Ordiene, Rasa
Zabiela, Vytautas
Zaliaduonyte, Diana
Gustiene, Olivija
Lapinskas, Tomas
Jurkevicius, Renaldas
author_facet Kazakauskaite, Egle
Vajauskas, Donatas
Bardauskiene, Lina
Ordiene, Rasa
Zabiela, Vytautas
Zaliaduonyte, Diana
Gustiene, Olivija
Lapinskas, Tomas
Jurkevicius, Renaldas
author_sort Kazakauskaite, Egle
collection PubMed
description OBJECTIVES: To find the imaging mortality predictors in patients with previous myocardial infarction (MI), symptomatic heart failure (HF), and reduced left ventricle (LV) ejection fraction (EF). METHODS: for the study 39 patients were selected prospectively with prior MI, symptomatic HF, and LVEF ≤40%. All patients underwent transthoracic echocardiography (TTE), single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI), 18F-FDG positron emission tomography (FDG PET). 31 patients underwent cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE). Patients were divided into two groups: 1 group – cardiac death; 2 group – no cardiac death. Myocardial scars were assessed on a 5-point-scale. Follow-up data was obtained. RESULTS: Imaging features disclosed significant difference (p < 0.05) of defect score (CMR and SPECT-PET), LV end-diastolic diameter (EDD) (TTE), LVEDD index (CMR), LV global longitudinal strain (CMR) and LV global circumferential strain (CMR) between the groups. Predictors of cardiac death were: LVEDD index (TTE) and LV global longitudinal strain. The cut-off values to predict cardiac death were: defect score (CMR) 25 (AUC, 79.5%; OR 1.8, 95% CI 1.2–2.7), SPECT-PET defect score 22 (AUC, 73.9%; OR 0.5, 95% CI 0.3–0.7), LVEDD (TTE) 58 mm (AUC, 88.4%; OR 23.6, 95% CI 2.6–217.7), LVEDDi 30 mm/m(2) (TTE) (AUC, 73.6%; OR 22.0, 95% CI 1.9–251.5), LVEDDi 33.6 mm/m(2) (CMR) (AUC, 73.6%; OR 22.0, 95% CI 1.9–251.5), LV global longitudinal strain −13.4 (AUC, 87.8%; OR 2.1, 95% CI 1.2–3.7) and LV global circumferential strain −16.3 (AUC, 76.1%; OR 1.9, 95% CI 1.2–3.0). CONCLUSIONS: Imaging features, such as defect score (CMR) >25, SPECT-PET defect score >22, LVEDD (TTE) >58 mm, LVEDDi (TTE) >30 mm/m(2), LVEDDi (CMR) >33.6 mm/m(2), LV global longitudinal strain −13.4 and LV global circumferential strain −16.3, may increase sensitivity and specificity of FDG PET and LGE CMR predicting of late mortality.
format Online
Article
Text
id pubmed-10466976
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-104669762023-08-31 The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure Kazakauskaite, Egle Vajauskas, Donatas Bardauskiene, Lina Ordiene, Rasa Zabiela, Vytautas Zaliaduonyte, Diana Gustiene, Olivija Lapinskas, Tomas Jurkevicius, Renaldas Perfusion Original Papers OBJECTIVES: To find the imaging mortality predictors in patients with previous myocardial infarction (MI), symptomatic heart failure (HF), and reduced left ventricle (LV) ejection fraction (EF). METHODS: for the study 39 patients were selected prospectively with prior MI, symptomatic HF, and LVEF ≤40%. All patients underwent transthoracic echocardiography (TTE), single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI), 18F-FDG positron emission tomography (FDG PET). 31 patients underwent cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE). Patients were divided into two groups: 1 group – cardiac death; 2 group – no cardiac death. Myocardial scars were assessed on a 5-point-scale. Follow-up data was obtained. RESULTS: Imaging features disclosed significant difference (p < 0.05) of defect score (CMR and SPECT-PET), LV end-diastolic diameter (EDD) (TTE), LVEDD index (CMR), LV global longitudinal strain (CMR) and LV global circumferential strain (CMR) between the groups. Predictors of cardiac death were: LVEDD index (TTE) and LV global longitudinal strain. The cut-off values to predict cardiac death were: defect score (CMR) 25 (AUC, 79.5%; OR 1.8, 95% CI 1.2–2.7), SPECT-PET defect score 22 (AUC, 73.9%; OR 0.5, 95% CI 0.3–0.7), LVEDD (TTE) 58 mm (AUC, 88.4%; OR 23.6, 95% CI 2.6–217.7), LVEDDi 30 mm/m(2) (TTE) (AUC, 73.6%; OR 22.0, 95% CI 1.9–251.5), LVEDDi 33.6 mm/m(2) (CMR) (AUC, 73.6%; OR 22.0, 95% CI 1.9–251.5), LV global longitudinal strain −13.4 (AUC, 87.8%; OR 2.1, 95% CI 1.2–3.7) and LV global circumferential strain −16.3 (AUC, 76.1%; OR 1.9, 95% CI 1.2–3.0). CONCLUSIONS: Imaging features, such as defect score (CMR) >25, SPECT-PET defect score >22, LVEDD (TTE) >58 mm, LVEDDi (TTE) >30 mm/m(2), LVEDDi (CMR) >33.6 mm/m(2), LV global longitudinal strain −13.4 and LV global circumferential strain −16.3, may increase sensitivity and specificity of FDG PET and LGE CMR predicting of late mortality. SAGE Publications 2022-05-03 2023-09 /pmc/articles/PMC10466976/ /pubmed/35503304 http://dx.doi.org/10.1177/02676591221100739 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Papers
Kazakauskaite, Egle
Vajauskas, Donatas
Bardauskiene, Lina
Ordiene, Rasa
Zabiela, Vytautas
Zaliaduonyte, Diana
Gustiene, Olivija
Lapinskas, Tomas
Jurkevicius, Renaldas
The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure
title The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure
title_full The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure
title_fullStr The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure
title_full_unstemmed The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure
title_short The incremental value of myocardial viability, evaluated by 18F-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure
title_sort incremental value of myocardial viability, evaluated by 18f-fluorodeoxyglucose positron emission tomography, and cardiovascular magnetic resonance for mortality prediction in patients with previous myocardial infarction and symptomatic heart failure
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466976/
https://www.ncbi.nlm.nih.gov/pubmed/35503304
http://dx.doi.org/10.1177/02676591221100739
work_keys_str_mv AT kazakauskaiteegle theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT vajauskasdonatas theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT bardauskienelina theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT ordienerasa theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT zabielavytautas theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT zaliaduonytediana theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT gustieneolivija theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT lapinskastomas theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT jurkeviciusrenaldas theincrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT kazakauskaiteegle incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT vajauskasdonatas incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT bardauskienelina incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT ordienerasa incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT zabielavytautas incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT zaliaduonytediana incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT gustieneolivija incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT lapinskastomas incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure
AT jurkeviciusrenaldas incrementalvalueofmyocardialviabilityevaluatedby18ffluorodeoxyglucosepositronemissiontomographyandcardiovascularmagneticresonanceformortalitypredictioninpatientswithpreviousmyocardialinfarctionandsymptomaticheartfailure